• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Pharm Investig . Potential therapeutic and pharmacological strategies for SARS-CoV2

tetano

Editor, Senior Moderator
J Pharm Investig


. 2021 Mar 5;1-16.
doi: 10.1007/s40005-021-00520-4. Online ahead of print.
Potential therapeutic and pharmacological strategies for SARS-CoV2


Doaa A Ghareeb[SUP] 1 2 [/SUP], Samar R Saleh[SUP] 1 2 [/SUP], Mohammed S Nofal[SUP] 2 [/SUP], Mohamed M Y Kaddah[SUP] 2 [/SUP], Salma F Hassan[SUP] 2 [/SUP], Inas K Seif[SUP] 1 [/SUP], Sally A El-Zahaby[SUP] 3 [/SUP], Shaimaa M Khedr[SUP] 2 [/SUP], Marwa Y Kenawy[SUP] 4 [/SUP], Aliaa A Masoud[SUP] 1 [/SUP], Salma A Soudi[SUP] 2 [/SUP], Ahmed A Sobhy[SUP] 1 2 5 [/SUP], Jaillan G Sery[SUP] 2 [/SUP], Miral G Abd El-Wahab[SUP] 2 [/SUP], Alshimaa A Abd Elmoneam[SUP] 1 [/SUP], Abdulaziz Mohsen Al-Mahallawi[SUP] 6 7 [/SUP], Maha A El-Demellawy[SUP] 2 8 [/SUP]



Affiliations

Abstract

Background: At the end of 2019, the new Coronavirus disease 2019 (COVID-19) strain causing severe acute respiratory syndrome swept the world. From November 2019 till February 2021, this virus infected nearly 104 million, with more than two million deaths and about 25 million active cases. This has prompted scientists to discover effective drugs to combat this pandemic.
Area covered: Drug repurposing is the magic bullet for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Therefore, several drugs have been investigated in silico, in vitro, as well as through human trials such as anti-SARS-CoV2 agents, or to prevent the complications resulting from the virus. In this review, the mechanisms of action of different therapeutic strategies are summarized. According to the WHO, different classes of drugs can be used, including anti-malarial, antiviral, anti-inflammatory, and anti-coagulant drugs, as well as angiotensin-converting enzyme inhibitors, antibiotics, vitamins, zinc, neutralizing antibodies, and convalescent plasma therapy. Recently, there are some vaccines which are approved against SARS-CoV2.
Expert opinion: A complete understanding of the structure and function of all viral proteins that play a fundamental role in viral infection, which contribute to the therapeutic intervention and the development of vaccine in order to reduce the mortality rate.
Supplementary information: The online version contains supplementary material available at 10.1007/s40005-021-00520-4.

Keywords: COVID-19; Camostat; Hydroxychloroquine; Indomethacin; Teicoplanin; Tocilizumab.
 
Back
Top Bottom